BR112015003655A2 - composto; uso de um composto; e composição farmacêutica - Google Patents

composto; uso de um composto; e composição farmacêutica

Info

Publication number
BR112015003655A2
BR112015003655A2 BR112015003655A BR112015003655A BR112015003655A2 BR 112015003655 A2 BR112015003655 A2 BR 112015003655A2 BR 112015003655 A BR112015003655 A BR 112015003655A BR 112015003655 A BR112015003655 A BR 112015003655A BR 112015003655 A2 BR112015003655 A2 BR 112015003655A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
aromatic
halogen substituents
aminopyrimidine derivatives
Prior art date
Application number
BR112015003655A
Other languages
English (en)
Inventor
Solinas Antonio
De Forni Davide
Lori Franco
Kéri György
Chafouleas James
Órfi László
Greff Zoltán
Varga Zoltán
Original Assignee
Virostatics Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virostatics Srl filed Critical Virostatics Srl
Publication of BR112015003655A2 publication Critical patent/BR112015003655A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

resumo composto; uso de um composto; e composição farmacêutica determinados derivados aminopirimidínicos 4,6- dissubstituídos que possuem substituintes aromáticos e halogênicos.
BR112015003655A 2012-08-23 2013-08-23 composto; uso de um composto; e composição farmacêutica BR112015003655A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261692641P 2012-08-23 2012-08-23
PCT/US2013/056347 WO2014031937A1 (en) 2012-08-23 2013-08-23 Novel 4,6-disubstituted aminopyrimidine derivatives

Publications (1)

Publication Number Publication Date
BR112015003655A2 true BR112015003655A2 (pt) 2017-07-04

Family

ID=50148518

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015003655A BR112015003655A2 (pt) 2012-08-23 2013-08-23 composto; uso de um composto; e composição farmacêutica

Country Status (26)

Country Link
US (2) US9617225B2 (pt)
EP (1) EP2887943B1 (pt)
JP (2) JP6639231B2 (pt)
KR (1) KR102209229B1 (pt)
CN (1) CN104822380B (pt)
AU (1) AU2013305634B2 (pt)
BR (1) BR112015003655A2 (pt)
CA (1) CA2882733C (pt)
DK (1) DK2887943T3 (pt)
EA (1) EA029278B1 (pt)
ES (1) ES2661717T3 (pt)
HK (1) HK1213482A1 (pt)
HR (1) HRP20180285T1 (pt)
HU (1) HUE036288T2 (pt)
IL (2) IL237143A (pt)
LT (1) LT2887943T (pt)
MX (1) MX355354B (pt)
NO (1) NO2970314T3 (pt)
NZ (1) NZ705313A (pt)
PL (1) PL2887943T3 (pt)
SG (2) SG11201501041VA (pt)
SI (1) SI2887943T1 (pt)
TR (1) TR201802913T4 (pt)
UA (1) UA117814C2 (pt)
WO (1) WO2014031937A1 (pt)
ZA (1) ZA201501600B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2887943B1 (en) * 2012-08-23 2017-12-06 Virostatics Srl Novel 4,6-disubstituted aminopyrimidine derivatives
CN104151178B (zh) * 2014-08-06 2016-08-17 江苏鼎龙科技有限公司 2-氨基-4-(β-羟乙基氨基)苯甲醚及其硫酸盐的制备方法
ES2720525T3 (es) 2014-10-16 2019-07-22 Bayer Pharma AG Derivados fluorados de benzofuranil-pirimidina que contienen un grupo sulfona
AU2016279330B2 (en) 2015-06-16 2020-05-14 Jiangsu Hengrui Medicine Co., Ltd. Piperidine derivative and preparation method and pharmaceutical use thereof
WO2017055196A1 (en) 2015-09-29 2017-04-06 Bayer Pharma Aktiengesellschaft Novel macrocyclic sulfondiimine compounds
JP6888000B2 (ja) 2015-10-08 2021-06-16 バイエル ファーマ アクチエンゲゼルシャフト 新規な修飾された大環状化合物
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
EP3190103A1 (en) * 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
CA3057891A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
US11254690B2 (en) 2017-03-28 2022-02-22 Bayer Pharma Aktiengesellschaft PTEFb inhibiting macrocyclic compounds
CN109761909B (zh) * 2019-01-25 2022-08-26 中国药科大学 N-(4-(嘧啶-4-氨基)苯基)磺酰胺类抑制剂或其可药用的盐、其制备方法及用途
IT201900004737A1 (it) 2019-03-29 2020-09-29 Virostatics Srl Composti aventi attività enzimatica anti-CDK4/6 e anti-CDK9 per l’inibizione della proliferazione del cancro e relativi metodi di screening per la loro identificazione.
CN111269215B (zh) * 2020-04-01 2021-10-26 中科利健制药(广州)有限公司 含氮杂环有机化合物及其制备方法和应用
AU2021323245B2 (en) * 2020-08-07 2024-02-15 Pharmablock Sciences (Nanjing), Inc. CDK9 inhibitor and use thereof
WO2022195522A1 (en) * 2021-03-17 2022-09-22 Ildong Pharmaceutical Co., Ltd. Inhibitors of ano6 and their uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
US6757135B2 (en) 2000-07-28 2004-06-29 Seagate Technology Llc Leading edge bond pads
BR0113165A (pt) * 2000-08-08 2003-07-15 Ortho Mcneil Pharm Inc Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
US7419984B2 (en) 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
EP2316831B1 (en) * 2002-11-21 2013-03-06 Novartis AG 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
AU2004261484A1 (en) * 2003-07-30 2005-02-10 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
EP1678147B1 (en) * 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
US20090221581A1 (en) * 2005-05-25 2009-09-03 Philipp Wabnitz Methods of treating pain
WO2008129080A1 (en) 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
HU0900798D0 (en) 2009-12-21 2010-03-01 Vichem Chemie Kutato Kft 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
WO2013175415A1 (en) * 2012-05-23 2013-11-28 Piramal Enterprises Limited Substituted pyrimidine compounds and uses thereof
EP2887943B1 (en) * 2012-08-23 2017-12-06 Virostatics Srl Novel 4,6-disubstituted aminopyrimidine derivatives

Also Published As

Publication number Publication date
HRP20180285T1 (hr) 2018-04-20
ZA201501600B (en) 2020-12-23
CA2882733A1 (en) 2014-02-27
NZ705313A (en) 2018-03-23
SG11201501041VA (en) 2015-03-30
WO2014031937A1 (en) 2014-02-27
IL253061B (en) 2018-03-29
US10294218B2 (en) 2019-05-21
IL237143A (en) 2017-07-31
EA029278B1 (ru) 2018-03-30
MX355354B (es) 2018-04-17
UA117814C2 (uk) 2018-10-10
US20170204084A1 (en) 2017-07-20
DK2887943T3 (en) 2018-03-12
US20140057911A1 (en) 2014-02-27
CN104822380B (zh) 2019-01-01
CA2882733C (en) 2021-07-27
HUE036288T2 (hu) 2018-06-28
EP2887943A1 (en) 2015-07-01
JP6781736B2 (ja) 2020-11-04
KR20150064730A (ko) 2015-06-11
TR201802913T4 (tr) 2018-03-21
SI2887943T1 (en) 2018-04-30
AU2013305634B2 (en) 2018-03-22
EP2887943B1 (en) 2017-12-06
JP2015526479A (ja) 2015-09-10
NO2970314T3 (pt) 2018-05-12
ES2661717T3 (es) 2018-04-03
PL2887943T3 (pl) 2018-05-30
IL237143A0 (en) 2015-04-30
CN104822380A (zh) 2015-08-05
EP2887943A4 (en) 2016-01-13
AU2013305634A1 (en) 2015-03-12
US9617225B2 (en) 2017-04-11
LT2887943T (lt) 2018-05-25
EA201590417A1 (ru) 2015-07-30
JP2018197233A (ja) 2018-12-13
IL253061A0 (en) 2017-08-31
HK1213482A1 (zh) 2016-07-08
JP6639231B2 (ja) 2020-02-05
SG10201701438QA (en) 2017-03-30
MX2015002270A (es) 2015-08-14
KR102209229B1 (ko) 2021-01-29

Similar Documents

Publication Publication Date Title
BR112015003655A2 (pt) composto; uso de um composto; e composição farmacêutica
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2016002148A1 (es) Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos.
CL2016000925A1 (es) Inhibidores de bromodominio
NI201400150A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
CR20160419A (es) Nuevos compuestos biciclicos
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
CL2015002473A1 (es) Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhibidores de la phd.
DOP2018000082A (es) NUEVOS DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
UY38712A (es) Lactamas fusionadas de arilo y heteroarilo
GT201400144A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112016000489A8 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
TR201909788T4 (tr) C4-monometil triterpenoid türevleri ve bunların kullanım yöntemleri.
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
BR112014030655A8 (pt) Compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
BR112015008389A2 (pt) compostos úteis na síntese de compostos de benzamida
BR112015027394A2 (pt) derivados de pirrolo[2,3-d]pirimidina como agonistas de receptor cb2

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements